Abstract
The expression of drebrin, a cytoskeletal protein newly estimated by expression profiling to correlate with the genotype and prognosis of B-cell precursor acute lymphoblastic leukemia (BCP-ALL), was examined by independent methods. After demonstrating its higher expression in TEL/AML1(pos) BCP-ALL by quantitative reverse transcriptase polymerase chain reaction, we developed an anti-drebrin monoclonal antibody (mAb). In a cohort of 86 children with BCP-ALL, we found increased expression of drebrin in TEL/AML1(pos) ALL. In conclusion, relationship of drebrin expression and prognosis or genotype can now be assessed using flow cytometry.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acute Disease
-
Animals
-
Antibodies, Monoclonal / immunology*
-
Core Binding Factor Alpha 2 Subunit
-
Flow Cytometry
-
Humans
-
Mice
-
Neuropeptides / immunology*
-
Neuropeptides / metabolism*
-
Oncogene Proteins, Fusion
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology*
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism*
-
Prognosis
-
RNA, Messenger / genetics
-
Reverse Transcriptase Polymerase Chain Reaction
Substances
-
Antibodies, Monoclonal
-
Core Binding Factor Alpha 2 Subunit
-
Neuropeptides
-
Oncogene Proteins, Fusion
-
RNA, Messenger
-
TEL-AML1 fusion protein
-
drebrins